SuperworthAspire Biopharma ASBP
- Market cap
- $12.3M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 126×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $97.7K
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Aspire Biopharma trades at 126× sales. Revenue was $97.7K over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1.9K | $4.3K | $28.4K | $63.1K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1.1K | $5.3K | $22.6K | $93.2K |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $884 | −$1K | $5.8K | −$30.1K |
| R&D | n/a | n/a | $10.5K | $10.5K | $7K | $116.4K | $263.1K+2406% | $352.9K+3261% | $207.9K+2870% | $100K−14% | $296.7K+13% | $233.5K−34% |
| SG&A | $324.7K+27% | $402.6K+28% | $220.5K−32% | $501K+74% | $208.3K−36% | $551.4K+37% | $15.3M+6837% | $447K−11% | $938.5K+351% | $1.7M+217% | $1.4M−91% | $2.2M+389% |
| n/a | n/a | n/a | n/a | −$215.3K | −$667.7K | −$15.6M | −$799.9K | −$1.1M+432% | −$1.8M+177% | −$1.6M−89% | −$2.7M+235% | |
| Interest expense | n/a | n/a | $183.3K | n/a | n/a | n/a | $289.9K+58% | $527.9K | $1.5M | $6.2M | $1.6M+450% | $0 |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$15.9M | −$2M | n/a | n/a | −$3.2M−80% | −$1.3M−36% |
| n/a | n/a | n/a | n/a | $1K | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$69.3K | −$150.9K | −$231K | −$96.9K | −$216.3K+212% | −$765.7K+407% | −$15.9M+6802% | −$2M+1944% | −$1.9M+756% | −$4.7M+515% | −$3.2M−80% | −$1.3M−36% |
| −$12.00 | −$24.00 | −$12.00 | $0.00 | −$12.00+0% | −$1380.00+5650% | −$0.50−96% | −$48.19 | −$48.00+300% | n/a | −$20.57+3974% | −$1.22−98% | |
| 7.5K−69% | 7.5K+25% | 23K−4% | 23K+74% | 23K+207% | 6.5K−14% | 31.6M+137185% | 41.1K+79% | 41.3K+79% | n/a | 156.7K−100% | 1M+2425% |
EPS, diluted: 3 periods, Q4 FY22 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Aspire Biopharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ASBPAspire Biopharma | $12.3M | n/m | 23.4× | 126× | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Aspire Biopharma
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .